Institution

Hospital Clínic de Barcelona

Barcelona, SpainWebsite

852running trials
412closed trials
67,185publications (OpenAlex)

Running trials

Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
NCT07593040· Phase 2· Vall d'Hebron Institute of Oncology· Source
Not yet recruiting
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
NCT07502781· Hospital Clinic of Barcelona· Source
Not yet recruiting
High Flow Nasal Oxygenation in Transcatheter Aortic Valve Replacement Procedures. TAVR-Highflow II
NCT07059728· Hospital Clinic of Barcelona· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
NCT07679269· Phase 2· Novartis Pharmaceuticals· Source
Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR
NCT07696182· Abbott Medical Devices· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Recruiting
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
NCT07773727· Phase 2· argenx· Source
Not yet recruiting
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT07901868· Phase 2· PETHEMA Foundation· Source
Not yet recruiting
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
2026-527617-29-00· Phase 3· Systimmune Inc.· Source
Not yet recruiting
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
NCT07192471· Phase 1· Kyowa Kirin Inc.· Source
Not yet recruiting
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
NCT07929740· Phase 1· Kura Oncology, Inc.· Source
Recruiting
Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
2026-526026-40-00· Phase 2/3· Gilead Sciences Inc.· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)
2025-523010-89-00· Phase 1/2· 35Pharma Inc.· Source
Recruiting
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458· Phase 3· Eli Lilly and Company· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Not yet recruiting
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source
Not yet recruiting
The MAB Trial: A Study of Tozorakimab to Reduce Lung Inflammation and Promote Lung Healing in People with COPD.
2025-522359-24-00· Phase 2· University Of Leicester· Source
Not yet recruiting
A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence
2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source
Not yet recruiting
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· Phase 2· Fundacion PETHEMA· Source
Not yet recruiting
Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Women With Gestational Diabetes
NCT07558291· Hospital Clinic of Barcelona· Source
Recruiting
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940· Phase 1/2· Boehringer Ingelheim· Source
Not yet recruiting
A Clinical Trial of Analytical Treatment Interruption in People With HIV With a Highly Favourable Profile
NCT07875504· Phase 4· Fundacion Clinic per a la Recerca Biomédica· Source
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· Phase 2· NS Pharma, Inc.· Source
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
NCT07705607· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL
2025-524915-36-00· Phase 1/2· Glaxosmithkline Research & Development Limited· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264· Phase 3· CSL Behring· Source
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· Phase 2· Bristol-Myers Squibb· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· AstraZeneca AB· Source
Not yet recruiting
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
NCT07717099· Phase 2· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source
Not yet recruiting
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
2026-527365-30-00· Phase 1/2· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source
Not yet recruiting
Same-Day Versus Standard Hospital Discharge After TAVI (HOME-TAVI)
NCT07738575· Hospital Clinic of Barcelona· Source
Not yet recruiting
A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease
2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
A Mediterranean Diet-Based Culinary Intervention in Adults With Metabolic Syndrome
NCT07702695· Fundacion Clinic per a la Recerca Biomédica· Source
Not yet recruiting
Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population
2025-523070-16-00· Phase 4· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source
Recruiting
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162· Phase 4· RECORDATI GROUP· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-524711-36-00· Phase 3· Alkermes Inc.· Source

Showing 50 of 852.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer57 recruiting
Multiple myeloma31 recruiting
Prostate cancer30 recruiting
Metastatic breast cancer28 recruiting
Colorectal cancer23 recruiting
Pancreatic cancer23 recruiting
Childhood cancers21 recruiting
Melanoma20 recruiting
Gastric and oesophageal cancer17 recruiting
Acute myeloid leukaemia16 recruiting
Ovarian cancer16 recruiting
Bladder cancer15 recruiting
Heart failure15 recruiting
Chronic lymphocytic leukaemia13 recruiting
High blood pressure13 recruiting
Liver and biliary tract cancer13 recruiting
Endometrial cancer12 recruiting
Coronary artery disease11 recruiting
Liver cirrhosis10 recruiting
Bronchiectasis9 recruiting
Obesity9 recruiting
Pulmonary arterial hypertension9 recruiting
Acute lymphoblastic leukaemia8 recruiting
Alzheimer disease8 recruiting
Head and neck cancer8 recruiting
Idiopathic pulmonary fibrosis8 recruiting
Kidney cancer8 recruiting
Mantle cell lymphoma8 recruiting
Myelodysplastic syndromes8 recruiting
Narcolepsy8 recruiting
Aortic stenosis7 recruiting
Myeloproliferative neoplasms7 recruiting
Depression6 recruiting
Hodgkin lymphoma6 recruiting
Amyloidosis5 recruiting
Cervical cancer5 recruiting
Chronic kidney disease5 recruiting
Chronic myeloid leukaemia5 recruiting
COPD5 recruiting
Crohn's disease5 recruiting
Diffuse large B-cell lymphoma5 recruiting
Parkinson disease5 recruiting
Primary biliary cholangitis5 recruiting
Stroke5 recruiting
Triple-negative breast cancer5 recruiting
Asthma4 recruiting
Atrial fibrillation4 recruiting
Brain metastases4 recruiting
Cystic fibrosis4 recruiting
Deep vein thrombosis and pulmonary embolism4 recruiting
Follicular lymphoma4 recruiting
HIV4 recruiting
Myasthenia gravis4 recruiting
Schizophrenia4 recruiting
Epidermolysis bullosa3 recruiting
Fatty liver disease (MASLD/MASH)3 recruiting
IgA nephropathy3 recruiting
Lupus (SLE)3 recruiting
Multiple sclerosis3 recruiting
Type 2 diabetes3 recruiting
Autism2 recruiting
Bipolar disorder2 recruiting
Cytomegalovirus infection2 recruiting
Diabetic eye disease2 recruiting
Frontotemporal dementia2 recruiting
Graves' disease2 recruiting
Hepatitis B2 recruiting
Huntington's disease2 recruiting
Hypertrophic cardiomyopathy2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Obstructive sleep apnoea2 recruiting
Sarcoidosis2 recruiting
Type 1 diabetes2 recruiting
Ulcerative colitis2 recruiting
Aortic aneurysm1 recruiting
Chronic rhinosinusitis with nasal polyps1 recruiting
Cushing's syndrome1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Dilated cardiomyopathy1 recruiting
Endometriosis1 recruiting
Epilepsy1 recruiting
Fibromyalgia1 recruiting
Gestational diabetes1 recruiting
Glaucoma1 recruiting
Glioblastoma1 recruiting
Hypothyroidism1 recruiting
Macular degeneration1 recruiting
Mesothelioma1 recruiting
Mild cognitive impairment1 recruiting
Mitochondrial disease1 recruiting
Osteoarthritis1 recruiting
Psoriasis1 recruiting
Rheumatoid arthritis1 recruiting
Sickle cell disease1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Thyroid cancer1 recruiting
Ventricular tachycardia1 recruiting

Closed trials

Withdrawn
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
NCT07084831· Phase 3· European Group for Research In Schizophrenia· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
NCT07224672· Phase 2· GlaxoSmithKline· Source
Completed
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
2025-524038-24-00· Phase 3· Praxis Precision Medicines Inc.· Source
Completed
A phase 1 Clinical Trial to Evaluate Safety and Immunogenecity of HIV SOSIP v8.2 763 Vaccine in healthy individuals
2025-520529-19-00· Phase 1· Consorcio Centro De Investigacion Biomedica En Red· Source
Completed
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
2024-519537-29-00· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07424144· Phase 3· Sanofi· Source
Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Novartis Pharma AG· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
2025-521480-12-00· Phase 1· Atavistik Bio Inc.· Source
Terminated
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
NCT06987968· Phase 2· Genfit· Source
Completed
A Study With CIT-013 in RA Patients
NCT06567470· Phase 2· Citryll BV· Source
Completed
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05896163· Phase 1/2· Pfizer Inc.· Source
Active, not recruiting
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
2024-517818-15-00· Phase 1/2· Merck Healthcare KGaA· Source
Active, not recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis
NCT07028879· Hospital Clinic of Barcelona· Source
Completed
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
2024-512505-66-00· Phase 2/3· Gilead Sciences Inc.· Source
Completed
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
NCT06855056· European Foundation for Study of Chronic Liver Failure· Source
Completed
Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
NCT06837090· Grupo Espanol de Tumores Neuroendocrinos· Source
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973786· Phase 3· Dr. Inge Winter· Source
Active, not recruiting
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· Phase 3· AbbVie· Source
Active, not recruiting
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source
Completed
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
2023-508998-85-00· Phase 1· Boehringer Ingelheim International GmbH· Source
Completed
A trial to learn how well NMS-01940153E works in combination with atezolizumab and priming administration of decitabine or with atezolizumab alone in patients with hepatocellular carcinoma (HCC) that cannot be removed by surgery and who received prior treatment with other anti-cancer medicines
2024-516737-12-00· Phase 2· Nerviano Medical Sciences S.r.l.· Source
Active, not recruiting
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06604715· Phase 1· Janssen Research & Development, LLC· Source
Terminated
Respiratory Syncytial Virus Infection In Exacerbations of Chronic Obstructive Pulmonary Diasease: The RECODE Study
NCT06735612· Fundacio Privada Mon Clinic Barcelona· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698· Phase 2· Novo Nordisk A/S· Source
Completed
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers
2023-507674-41-00· Phase 1· Novartis Pharma AG· Source
Completed
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma
2024-511949-19-00· Phase 1· Sairopa B.V.· Source
Completed
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)
2024-514559-13-00· Phase 2/3· Praxis Precision Medicines Inc.· Source
Completed
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source
Completed
A multicentre clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy
2024-519275-26-00· Phase 1/2· Fundacion PETHEMA· Source
Completed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
A Study of TAK-861 in People With Narcolepsy Type 1
NCT06505031· Phase 3· Takeda· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Active, not recruiting
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· Phase 2· GlaxoSmithKline· Source
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973851· Phase 3· Dr. Inge Winter· Source
Terminated
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
NCT06524739· Phase 3· CSL Behring· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874· Phase 2· Novo Nordisk A/S· Source
Completed
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody
NCT04309981· Phase 2· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source
Completed
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783· Phase 2· Alkermes, Inc.· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Completed
Open-Label Study of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab in Subjects with Chronic HBV Infection
NCT06245291· Phase 2· Arbutus Biopharma Inc.· Source
Completed
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· Phase 3· Ipsen· Source
Completed
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
NCT06470828· Phase 3· Takeda· Source
Completed
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
NCT05876078· Revamp Medical Ltd.· Source
Completed
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.
NCT06173505· Phase 1/2· Xencor Inc.· Source

Showing 50 of 412.

Registry name variants (91)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Hospital Clinic de Barcelona
Barcelona, Barcelona 08036
1,129 trials
Hospital Clinic Barcelona
Barcelona, 08036
66 trials
Hosp Clinic de Barcelona
Barcelona, 08036
21 trials
Hospital Clinic of Barcelona
Barcelona, 08036
19 trials
Hospital Clínic de Barcelona (Dermatology service)
Barcelona, 08036
3 trials
- NCT06605443Precision Medicine for L/GCMN and Melanoma 2
  Contact: Susana Puig Sardà, PhD, MD
- NCT06608420Precision Medicine for L/GCMN and Melanoma 1
  Contact: Susana Puig Sardà, PhD, MD
- NCT06605417Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
  Contact: Susana Puig Sardà, PhD, MD
Hospital Clinic de Barcelona (ICCV)
Barcelona, L'Eixample 08036
2 trials
- NCT05427370The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
  Contact: Jorge Alcocer
- NCT03217006Randomization of Single vs Multiple Arterial Grafts
  Contact: Jorge Alcocer
602 - Hospital Clínic de Barcelona
Barcelona, 08036
1 trial
- NCT03666780Lifetech LAmbre™ Left Atrial Appendage (LAA) Closure System Post-Market Clinical Follow-up Study
7240033 - Hospital Clínic de Barcelona
Barcelona, 08036
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Barcelona Clinic Hospital
Barcelona, Catalonia 08036
1 trial
- NCT07061054Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System
  Contact: Pablo Iglesias García, Msc, RN
Center for Neuroimmunology. Advanced Imaging in Neuroimmunological Diseases lab (ImaginEM). Hospital Clinic Barcelona
Barcelona, Barcelona 08036
1 trial
- NCT04988880Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program
Clinic Hospital Barcelona
Barcelona
1 trial
- NCT04753749Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy
Clinic Hospital of Barcelona
Barcelona, 08036
1 trial
- NCT06127901Prevalence and Risk Factors for Postoperative Delirium 48 Hours After Surgery
Department of Gastroenterology, Hospital Clínic de Barcelona, University of Barcelona
Barcelona
1 trial
- NCT05732623Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
  Contact: Francesc Balaguer Prunès
Department of Medical Oncology, Hospital Clinic of Barcelona
Barcelona
1 trial
- NCT06044623Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
  Contact: Raquel Gomez, Dr
Hosp. Clínic of Barcelona
Barcelona, 08036
1 trial
- NCT05976685Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
  Contact: Xavier Freixa
HOSPITAL CLINIC BARCELONA - Hematology department
Barcelona, 8036
1 trial
- NCT06284122Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Hospital Clinic Barcelona, Liver ICU
Barcelona, Catalonia 08036
1 trial
- NCT05917327Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease
Hospital Clínic Barcelona (Site 3080)
Barcelona, 08036
1 trial
- NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Hospital Clinic (Barcelona, Spain)
Barcelona
1 trial
- NCT06292988Predictive Factors for Medullary Thyroid Cancer Aggressiveness
Hospital Clinic de Barcelona, C/ Villarroel, 170
Barcelona, 08036
1 trial
- NCT05817942Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
HOSPITAL CLÍNIC DE BARCELONA-Department of Medical Oncology (Site 0043)
Barcelona, Catalonia 08036
1 trial
- NCT05017012A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Hospital Clinic de Barcelona /ID# 1142-0533
Barcelona, 08036
1 trial
- NCT02910583Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Hospital Clinic de Barcelona /ID# 221106
Barcelona, 08036
1 trial
- NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Hospital Clinic de Barcelona /ID# 226695
Barcelona, 08036
1 trial
- NCT04903626Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Hospital Clinic de Barcelona /ID# 246543
Barcelona, 08036
1 trial
- NCT05618028Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Hospital Clinic de Barcelona /ID# 275476
Barcelona, 08036
1 trial
- NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Hospital Clínic de Barcelona - Maternitat
Barcelona, 08028
1 trial
- NCT07502781Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
  Contact: Miguel Maria Alsina Casanova, MD
Hospital Clinic de Barcelona, Neurology Service, scale 8-4th floor
Barcelona, 08036
1 trial
- NCT05687903A Study of TAK-861 in Participants With Narcolepsy Type 1
Hospital Clinic de Barcelona - Servicio de Oncologia
Barcelona, 08036
1 trial
- NCT05327530A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Hospital Clinic de Barcelona - Servicio de Oncología Médica
Barcelona, 08036
1 trial
- NCT04887831Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
HOSPITAL CLINIC DE BARCELONA, SEU PLATO
Barcelona, 08006
1 trial
- NCT05518123Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Hospital Clinic de Barcelona (Site 0092)
Barcelona, 08008
1 trial
- NCT04165798KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
  Contact: Study Coordinator
Hospital Clinic de Barcelona (Site 0261)
Barcelona, 08036
1 trial
- NCT03783078Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Hospital Clinic de Barcelona (Site 1100)
Barcelona, Barcelona [Barcelona] 08036
1 trial
- NCT03631784A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
Hospital Clinic de Barcelona (Site 1821)
Barcelona, 08036
1 trial
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología
Barcelona, 08036
1 trial
- NCT04408625Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Hospital Clinic in Barcelona
Barcelona
1 trial
- NCT04613921Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
  Contact: Javier Fernández Gómez
Hospital Clinic of Barcelona, Department of Hematology
Barcelona, 08036
1 trial
- NCT06514807A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer (Hospital Clínic de Barcelona)
Barcelona, Barcelona 08035
1 trial
- NCT07702695A Mediterranean Diet-Based Culinary Intervention in Adults With Metabolic Syndrome
  Contact: Victoria S Pinto Manzo, Msc
Oncology Department, Hospital Clínic de Barcelona
Barcelona
1 trial
- NCT04879563Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
Unidad de Arritimias, Hospital Clínic Barcelona
Barcelona
1 trial
- NCT06543173Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator
  Contact: Ivo Roca Luque, MD
7240112 - Hospital Clinic Barcelona
Barcelona, 08036
Hospital Clinic de Barcelona
Badalona, 08036
Hospital Clinic de Barcelona /ID# 150598
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 153255
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 157552
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 159462
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 201878
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 202726
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 210564
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 218007
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 223355
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 226651
Barcelona, Barcelona 08036
Hospital Clinic de Barcelona /ID# 242978
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 245374
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 260492
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 263040
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 265415
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 269408
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 269789
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 271452
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 274262
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 276412
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 276468
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 276878
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 278532
Barcelona, 08036
Hospital Clinic de Barcelona /ID# 281271
Barcelona, 08036
Hospital Clinic De Barcelona - Myeloma and Amyloidosis Unit
Barcelona
Hospital Clinic de Barcelona - Neurología
Barcelona
Hospital Clinic De Barcelona - Oncología Médica
Barcelona, 8036
Hospital Clinic de Barcelona - Planta 4 Escalera
Barcelona, 8036
Hospital Clinic de Barcelona, Psychiatry and Psychology Dept.
Barcelona, 08036
Hospital Clinic de Barcelona - Sede Villarroel - Rheumatology
Barcelona, 08036
Hospital Clinic de Barcelona (Site 0452)
Barcelona, 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 0481)
Barcelona, Catalonia 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 0707)
Barcelona, Catalonia 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 1202)
Barcelona, Catalonia 08036
Hospital Clinic de Barcelona (Site 1204)
Barcelona, 08036
Hospital Clinic de Barcelona (Site #1305)
Barcelona, 08036
Hospital Clinic de Barcelona (Site 1406)
Barcelona, Catalonia 08036
Hospital Clinic de Barcelona (Site 1602)
Barcelona, 08036
Hospital Clinic de Barcelona (Site 1810)
Barcelona, 08036
Hospital Clinic de Barcelona (Site 1919)
Barcelona, 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 2001)
Barcelona, Catalonia 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 2201)
Barcelona, Catalonia 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 2800)
Barcelona, Catalonia 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 3400)
Barcelona, 08036
Hospital Clinic de Barcelona (Site 3404)
Barcelona, 08036
HOSPITAL CLÍNIC DE BARCELONA (Site 4105)
Barcelona, Catalonia 08036
Hospital Clínic de Barcelona, Unidad de Trasplante Renal
Barcelona, 08036
Hospital Clinic De Barcelona - University of Barcelona
Barcelona, Catalonia 08036

Conditions

Diseases this institution publishes on or runs trials for.

Heart failure123 works · 27 trials
Liver and biliary tract cancer96 works · 32 trials
Melanoma91 works · 55 trials
Bipolar disorder86 works · 6 trials
HIV83 works · 21 trials
Schizophrenia67 works · 9 trials
Atrial fibrillation57 works · 9 trials
Crohn's disease53 works · 15 trials
Chronic kidney disease51 works · 12 trials
Bronchiectasis50 works · 13 trials
Asthma49 works · 8 trials
Ventricular tachycardia42 works · 1 trial
COPD41 works · 9 trials
Multiple sclerosis37 works · 10 trials
Multiple myeloma36 works · 77 trials
Lupus (SLE)34 works · 12 trials
Chronic rhinosinusitis with nasal polyps33 works · 4 trials
Metastatic breast cancer31 works · 69 trials
Deep vein thrombosis and pulmonary embolism26 works · 7 trials
Mild cognitive impairment24 works · 4 trials
Rheumatoid arthritis23 works · 5 trials
Pulmonary arterial hypertension23 works · 26 trials
Acute myeloid leukaemia23 works · 34 trials
Ulcerative colitis22 works · 7 trials
Psoriasis19 works · 8 trials
Frontotemporal dementia19 works · 5 trials
Antiphospholipid syndrome18 works · 0 trials
Macular degeneration17 works · 6 trials
Lewy body dementia17 works · 0 trials
Follicular lymphoma16 works · 11 trials

Institution data: ROR 02a2kzf50 (CC0-1.0)Updated 14 Nov 2026

Report an error